Aronne, L J <br/><br/>
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study.  [electronic resource] 

 -  International journal of obesity (2005)  May 2010 
 - 919-35 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1476-5497 
<br/><br/><label>Standard No.: </label>10.1038/ijo.2010.21  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Amides--administration & dosage<br/>Anti-Obesity Agents--administration & dosage<br/>Body Mass Index<br/>Body Weight--drug effects<br/>Diet, Reducing<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Male<br/>Metabolic Syndrome--drug therapy<br/>Middle Aged<br/>Obesity--drug therapy<br/>Pyridines--administration & dosage<br/>Receptor, Cannabinoid, CB1--agonists<br/>Risk Assessment<br/>Treatment Outcome<br/>Young Adult